4.4 Article

Investigating the Effects of Resveratrol on Chronically Ischemic Myocardium in a Swine Model of Metabolic Syndrome: A Proteomics Analysis

Journal

JOURNAL OF MEDICINAL FOOD
Volume 18, Issue 1, Pages 60-66

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/jmf.2014.0036

Keywords

metabolic syndrome; ischemic heart disease; proteomics; remodeling; metabolism; resveratrol

Funding

  1. National Heart, Lung, and Blood Institute [R01HL46716, R01HL69024, R01HL85647]
  2. NIH [5T32-HL094300-03, T32-HL0074]

Ask authors/readers for more resources

Resveratrol has been shown to improve cardiac perfusion and ventricular function after chronic ischemic injury. Using proteomic analysis, we sought to objectively investigate potential mechanisms, by which resveratrol exerts its cardioprotective effects in the setting of metabolic syndrome and chronic myocardial ischemia. Yorkshire swine were divided into two groups based on diet: high cholesterol (n=7) or a high-cholesterol diet with supplemental resveratrol (n=6). Four weeks later, all animals underwent surgical placement of an ameroid constrictor to their left circumflex artery. Diets were continued for another 7 weeks, and then the ischemic myocardium was harvested for proteomics analysis. Proteomic analysis identified 669 common proteins between the two groups. Of these proteins, 76 were statistically different, of which 41 were characterized (P<.05). Pathway analysis demonstrated that in animals supplemented with resveratrol, there was a downregulation in several proteins involved with mitochondrial dysfunction, cell death, and unfavorable cardiac remodeling. Furthermore, there was an upregulation in proteins involved in free radical elimination. We conclude that resveratrol supplementation significantly alters several critical protein markers in the chronically ischemic myocardium. Further investigation of these proteins may help elucidate the mechanisms by which resveratrol exerts its cardioprotective effects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Preadmission Cannabis Use Is Positively Correlated With Inpatient Opioid Dose Exposure in Hospitalized Patients With Inflammatory Bowel Diseases

Rahul S. Dalal, Sonali Palchaudhuri, Christopher K. Snider, James D. Lewis, Shivan J. Mehta, Gary R. Lichtenstein

Summary: The study found a significant positive correlation between preadmission cannabis use and inpatient opioid exposure among patients with inflammatory bowel disease. Additionally, first patient-reported pain score and preadmission opioid use were also associated with inpatient opioid exposure.

INFLAMMATORY BOWEL DISEASES (2021)

Editorial Material Gastroenterology & Hepatology

Superiority Complex: Do Teaching Hospitals Provide Inferior Care for IBD Patients?

Rahul S. Dalal, Gary R. Lichtenstein

DIGESTIVE DISEASES AND SCIENCES (2021)

Letter Gastroenterology & Hepatology

COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases

Rahul S. Dalal, Emma McClure, Jenna Marcus, Rachel W. Winter, Matthew J. Hamilton, Jessica R. Allegretti

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Editorial Material Gastroenterology & Hepatology

Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study

Rahul S. Dalal, Scott Esckilsen, Edward L. Barnes, Jordan C. Pruce, Jenna Marcus, Jessica R. Allegretti

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Endoscopy Is Not Associated with Infectious Adverse Events After Hematopoietic Cell Transplantation: A Retrospective Cohort Study

Abraham Segura, Rahul S. Dalal, Meghana Golla, James N. Gerson, Nadim Mahmud, James D. Lewis, Ravy K. Vajravelu

Summary: The study found that patients who underwent endoscopy after HCT did not have a higher risk of infectious adverse events compared to controls with similar immune statuses. These results may provide guidance for clinical decision-making regarding the risks and benefits of endoscopic management after HCT.

DIGESTIVE DISEASES AND SCIENCES (2022)

Article Gastroenterology & Hepatology

Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders

Rahul S. Dalal, Sanchit Gupta, Hannah Goodrick, Jennifer Mitri, Jessica R. Allegretti

INFLAMMATORY BOWEL DISEASES (2022)

Article Gastroenterology & Hepatology

Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naive Patients with Ulcerative Colitis

Rahul S. Dalal, Emma L. McClure, Jenna Marcus, Jessica R. Allegretti

Summary: This study compared the long-term drug survival of vedolizumab, adalimumab, and infliximab in patients with ulcerative colitis (UC). The results showed that vedolizumab had better survival rates than adalimumab for both clinical response and adverse effects, and vedolizumab also had better survival rates than infliximab for adverse effects.

DIGESTIVE DISEASES AND SCIENCES (2023)

Article Gastroenterology & Hepatology

Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series

Rahul S. Dalal, Kanwal Bains, Jenna Marcus, Emma L. McClure, Jessica R. Allegretti

Summary: In this case series, six patients with chronic pouchitis, cuffitis, or Crohn's-like disease of the pouch were treated with tofacitinib. One patient achieved a clinical response, but all patients eventually discontinued therapy due to nonresponse or adverse events.

INFLAMMATORY BOWEL DISEASES (2022)

Article Gastroenterology & Hepatology

Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases

Rahul S. Dalal, Jordan C. Pruce, Jessica R. Allegretti

Summary: In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure

Rahul S. Dalal, Puza P. Sharma, Kanwal Bains, Jordan C. Pruce, Jessica R. Allegretti

Summary: According to a retrospective cohort study, tofacitinib and ustekinumab demonstrated similar effectiveness in treating ulcerative colitis in patients who failed anti-tumor necrosis factor treatment. Adverse events observed were consistent with known safety profiles of these drugs.

INFLAMMATORY BOWEL DISEASES (2023)

Article Rheumatology

Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases

Rahul S. S. Dalal, Joerg Ermann, Alexander Carlin, Jennifer Mitri, Jessica R. R. Allegretti

Summary: This retrospective cohort study examined the disease activity of axial spondyloarthritis (axSpA) after initiation of anti-tumor necrosis factor (TNF) agents in patients with inflammatory bowel diseases (IBD). The study found that 52% of patients achieved symptom resolution (SR) of axSpA at 12 months after initiating anti-TNF therapy, and shorter IBD duration and adalimumab use were associated with higher odds of SR. Larger studies are needed to confirm these findings and explore additional predictors of SR and more effective therapeutics for this population.

CLINICAL RHEUMATOLOGY (2023)

Editorial Material Gastroenterology & Hepatology

Small Cells, Big Problems: Small Cell Carcinoma of the Rectal Cuff After Ileal-Pouch Anal Anastomosis in a Patient with Ulcerative Colitis

Rahul S. Dalal, Esther Baranov, Jessica Li, Xuefei Hong, Joshua Korzenik, Matthew Hamilton, Gila Sasson

DIGESTIVE DISEASES AND SCIENCES (2023)

Article Gastroenterology & Hepatology

Use of Tramadol vs Traditional Opioids and Adverse Outcomes in Patients with Inflammatory Bowel Disease: A Danish Nationwide Cohort Study

Rahul S. Dalal, Ken Lund, Floor D. Zegers, Sonia Friedman, Jessica R. Allegretti, Bente Mertz Norgard

Summary: The use of tramadol in patients with inflammatory bowel diseases (IBDs) was associated with lower odds of infection, bowel obstruction/ileus, and mortality compared to traditional opioids (TOs). These findings suggest that tramadol may be a safer option for pain management in IBD patients.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort

Rahul Dalal, Puza Sharma, Kanwal Bains, Jordan Pruce, Jessica Allegretti

Summary: Treatment with tofacitinib was effective in achieving steroid-free clinical remission for the majority of patients with UC through 78 weeks. Adverse events, which rarely required treatment discontinuation, were consistent with the known safety profile of tofacitinib.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study

Rahul S. Dalal, Govind Kallumkal, Heidy J. Cabral, Salam Bachour, Edward L. Barnes, Jessica R. Allegretti

Summary: In this retrospective cohort study, upadacitinib induction was shown to effectively achieve steroid-free clinical remission of ulcerative colitis for most patients. Rare adverse events leading to treatment discontinuation were consistent with the known safety profile of upadacitinib.

INFLAMMATORY BOWEL DISEASES (2023)

No Data Available